Sign in

TCRG on OTC

Cannaisseur Group Inc.

Cannaisseur Group Inc. is an American medicinal chemicals and botanical products company based in Atlanta.2 Its shares trade on OTC under the symbol TCRG.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with AIBOTICS, INC., NEUTRA CORP. or NUTRA PHARMA CORP, or pick any stock.

  • TickerTCRG on OTC2
  • IndustryMedicinal Chemicals & Botanical Products2
  • HeadquartersAtlanta, United States2
  • Incorporated inDE3
  • Business address650 Ponce De Leon Ave, Suite 300 #2334, Atlanta, Ga 303083
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company3
  • Legal formCorporation2
  • LEI529900YTQEMPSCJL69662
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o Harvard Business Services, Inc., 16192 Coastal Hwy, 19958 Lewes, United States2
  • Registered withDivision of Corporations, Department of State, 45243412

See how the biggest companies compare on our leaderboards

CBD-related products. Currently, the Company’s only assets and operations consist of the 51% interest it owns in Atlanta CBD, Inc.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-100.0%Revenue growth, 20255

Financial statements

Revenue675$0 in 2025
0$25.0K$50.0K$75.0K$100.0K2022: $88.1K$88.1K20222023: $53.1K$53.1K2023−40%2024: $700$7002024−99%2025: $0$02025
Gross profit675-$910 in 2025
-$20.0K0$20.0K$40.0K$60.0K2022: $45.3K$45.3K20222023: $26.2K$26.2K2023−42%2024: -$3.6K-$3.6K20242025: -$910-$9102025−75%
Operating income675-$1.7M in 2025+1768% since 2022
-$2.0M-$1.5M-$1.0M-$500.0K02022: -$91.9K-$91.9K20222023: -$189.9K-$189.9K2023+107%2024: -$1.3M-$1.3M2024+567%2025: -$1.7M-$1.7M2025+36%
Net income675-$1.8M in 2025+2113% since 2022
-$2.0M-$1.5M-$1.0M-$500.0K02022: -$80.1K-$80.1K20222023: -$128.0K-$128.0K2023+60%2024: -$1.3M-$1.3M2024+892%2025: -$1.8M-$1.8M2025+40%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Revenue, net of discounts$0$700
Cost of revenue$910$4.3K
Gross profit-$910-$3.6K
Selling, general and administrative expenses$1.7M$1.3M
Total operating expenses$1.7M$1.3M
Operating loss-$1.7M-$1.3M
Gain on settlement of accounts payable$3.8K$0
Loss on conversion of related party debt-$23.3K$0
Loss on settlement of mezzanine equity-$68.2K$0
Interest expense-$4.3K-$6.4K
Total other income (expense)-$91.9K-$6.4K
Net loss before taxes-$1.8M-$1.3M
Income tax benefit$0$0
Net loss-$1.8M-$1.3M
Less: Net loss attributable to minority interest-$34.5K-$3.6K
Net loss attributable to TCGI-$1.8M-$1.3M
Basic (in Shares)53.9M shares43.8M shares
Diluted (in Shares)53.9M shares43.8M shares
Basic (in Dollars per share)-$0.03-$0.03
Diluted (in Dollars per share)-$0.03-$0.03

Compare Cannaisseur Group Inc. with another company

What it owns

What Cannaisseur Group Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$225 Dec 31, 2025$5635 Dec 31, 2024−96.1%

Inventory

ItemLatestA year beforeChange
Inventory, total$1185 Dec 31, 2025$1.0K5 Dec 31, 2024−88.5%

Properties, in its own words

The Company has its principal offices located at 650 Ponce De Leon Ave, Suite 300 #2334, Atlanta, GA 30308.

Item 2 of the 10-K filed Mar 23, 2026.4

Leadership

Who has led Cannaisseur Group Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Floretta Gogo2024–now

President

  1. Floretta Gogo2024–now

Chief financial officer

  1. Carter Xavier2024–now

Chief operating officer

  1. Jamie Lee Brown2025–now
2025
Board members and other officers (6)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorXavier Carter named Feb 10, 2025 to Feb 13, 202517

Timeline

  1. Aug 28, 20258-K Regulation FD disclosure18
  2. May 12, 20258-K Regulation FD disclosure; Other events19
  3. May 5, 20258-K Executive or director change; Regulation FD disclosure; Other events20
  4. Mar 21, 20258-K Other events21
  5. Feb 6, 20258-K Executive or director change22
  6. Feb 6, 20258-K Executive or director change23
  7. Feb 5, 20258-K Other events24
  8. Mar 12, 2024New chief executive Floretta Gogo becomes CEO10
  9. Dec 22, 2020Founded Cannaisseur Group Inc. is founded2

Filings

72 filings to the SEC since October 2021: 3 annual reports, 9 quarterly reports, 7 major events, 20 insider forms, 7 private raises, 26 other. The latest 20:

  1. Aug 12, 202610-Q EDGAR
  2. May 11, 202610-Q EDGAR
  3. Mar 23, 202610-K EDGAR
  4. Nov 18, 202510-Q EDGAR
  5. Nov 13, 2025NT 10-Q EDGAR
  6. Sep 9, 202510-Q EDGAR
  7. Aug 28, 20258-K EDGAR
  8. Aug 15, 2025NT 10-Q EDGAR
  9. Aug 15, 20254 EDGAR
  10. Aug 15, 20254 EDGAR
  11. Aug 15, 20254 EDGAR
  12. Aug 15, 20254 EDGAR
  13. Jul 21, 202510-Q EDGAR
  14. May 16, 2025NT 10-Q EDGAR
  15. May 12, 20258-K EDGAR
  16. May 5, 20258-K EDGAR
  17. Mar 28, 2025EFFECT EDGAR
  18. Mar 27, 2025POS AM EDGAR
  19. Mar 21, 20258-K EDGAR
  20. Mar 21, 202510-K EDGAR

The 72 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jan 22, 2025Raised $90,000 in a private offering of equity Form D: 2 investors so far Form D
  2. Dec 27, 2024Raised $1,000 in a private offering of equity Form D: 1 investor so far Form D
  3. Nov 14, 2024Raised $5,000 in a private offering of equity Form D: 1 investor so far Form D
  4. Feb 15, 2023Raised $71,548 in a private offering of equity Form D: 3 investors so far Form D
  5. Apr 27, 2022Raised $42,560 in a private offering of equity Form D: 3 investors so far Form D
  6. Jul 7, 2021Raised $54,000 in a private offering of equity Form D: 4 investors so far Form D
  7. Dec 22, 2020Raised $171,000 in a private offering of equity Form D: 2 investors so far Form D

SEC filer profile

How Cannaisseur Group Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCannaisseur Group Inc.1
  • CIK0001879270
  • Employer ID (EIN)86-19075614
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2833 Medicinal Chemicals & Botanical Products1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address650 Ponce De Leon Ave, Suite 300 #2334, Atlanta, GA 303081
  • Phone404-254-21001
  • Shares outstanding60,459,890 as of Aug 12, 20269
  • Public float$2.7M as of Jun 30, 20254
  • AuditorM&K CPAS, PLLC, The Woodlands, Texas PCAOB ID 2738; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceFeb 14, 20221
  • Filings72 in all: 4 (14), 10-Q (9), 8-K (7), D (7), 3 (6), CORRESP (6), NT 10-Q (5), S-1/A (5)1
    All 15 form types

    UPLOAD (4), 10-K (3), EFFECT (2), 8-A12G (1), NT 10-K (1), POS AM (1), S-1 (1)

  • Latest filingsAnnual report (10-K) Mar 23, 2026
    Quarterly report (10-Q) Aug 12, 2026
    Latest 8-K (8-K) Aug 28, 2025

Securities registered for trading

ClassSymbolExchange
None

From the cover page of the 10-K filed Mar 23, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Cannaisseur Group Inc. names in Item 1A of its 10-K filed Mar 23, 2026: 38 risks under these headings, as written.4

  • A pandemic, epidemic or outbreak of an infectious disease in the markets in which the Company operates or that otherwise impacts its facilities and customers could adversely impact the Company’s business.
  • Our industry may become subject to expanded regulation and increased enforcement by the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC)
  • Increases in the cost of ingredients, labor and other costs could adversely affect our operating results.
  • We do not have long-term contracts with many of our suppliers, and as a result they could seek to increase prices or fail to deliver.
  • Risks Related to Our Dependence on Third Parties
  • Any prolonged disruption in the operations of any of our packaging facilities could harm our business.
  • Loss of key personnel or our inability to attract and retain new qualified personnel could hurt our business and inhibit our ability to operate and grow successfully.
  • We may not be able to adequately protect our intellectual property, which could harm the value of our brand and branded products and adversely affect our business.
  • Pandemics, natural disasters and geo-political events could adversely affect the Company’s business.
  • We do not have any outside Board of Directors which could create a conflict of interests and pose a risk from a corporate governance perspective.
  • Cyber security risks and the failure to maintain the integrity of internal, partner, and consumer data could result in damages to our reputation, the disruption of operations and/or subject us to costs, fines or lawsuits.
  • Risks Relating to Our Financial Condition
The other 28 risks
  • All businesses are affected by an unstable economy.
  • We have a limited operating history and operate in a new industry, and we may not succeed.
  • Our financial statements may not be comparable to those of other companies.
  • The success of our new and existing products and services is uncertain.
  • We cannot predict our future capital needs, and we may not be able to secure additional financing.
  • Our annual and quarterly financial results are subject to significant fluctuations depending on various factors, many of which are beyond our control, which could adversely affect our ability to satisfy our debt obligations as they become due.
  • As we expand our operations, we may be unable to successfully manage our future growth.
  • Any future litigation could have a material adverse impact on our results of operations, financial condition and liquidity, particularly since we do not currently have director and officer (“D&O”) insurance. Our lack of insurance may also make it difficult for us to retain and attract talented and skilled directors and officers. While we intend to apply for D&O insurance, we cannot guarantee that such application will be accepted.
  • The Company may be unable to manage growth, which may impact its potential profitability.
  • The Company operates in a highly competitive environment, and if it is unable to compete with its competitors, its business, financial condition, results of operations, cash flows and prospects could be materially adversely affected.
  • The Company may not be able to compete successfully with other established companies offering the same or similar services and, as a result, the Company may not achieve its projected revenue and user targets.
  • Our prior operating results may not be indicative of our future results.
  • The Company does not expect to pay dividends in the future; any return on investment may be limited to the value of the Company’s common stock.
  • Risks Related to Investment
  • Our stock is quoted on the OTC Market. The common stock price is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond the Company’s control or unrelated to its operating performance.
  • An active and visible public trading market for our common stock may not develop.
  • The market price of our common stock may be volatile.
  • Our issuance of additional common stock or preferred stock may cause our common stock price to decline, which may negatively impact your investment.
  • Our common stock is subject to the SEC’s penny stock rules and accordingly, broker-dealers may have trouble in completing customer transactions and trading activity in our securities may be adversely affected.
  • The market for penny stocks has experienced numerous frauds and abuses, which could adversely impact investors in our stock.
  • Sales by our stockholders of a substantial number of shares of our common stock in the public market could adversely affect the market price of our common stock.
  • Our business is dependent upon continued market acceptance by consumers.
  • The ability to hire additional qualified employees, and the timing of such hiring and our ability to control costs. We may require additional capital to finance our operations in the future, but that capital may not be available when it is needed and could be dilutive to existing stockholders.
  • Requirements associated with being a reporting public company will require significant company resources and management attention.
  • We are an emerging growth company and, as a result of the reduced disclosure and governance requirements applicable to emerging growth companies, our common stock may be less attractive to investors.
  • We do not expect to pay any cash dividends in the foreseeable future.
  • We can sell additional shares of common stock without consulting stockholders and without offering shares to existing stockholders, which would result in dilution of existing stockholders’ interests in the Company and could depress our stock price.
  • Because we will be subject to “penny stock” rules, the level of trading activity in our stock may be reduced.
  • Financial Industry Regulatory Authority (FINRA) sales practice requirements may also limit your ability to buy and sell our stock, which could depress our share price.

Legal proceedings

We are not currently involved in any litigation nor to our knowledge, is any litigation threatened against us, the outcome of which would, in our judgment based on information currently available to us, have a material adverse effect on our financial position or results of operations.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
    SEC EDGAROther events
  22. 22
  23. 23
  24. 24
    SEC EDGAROther events